GLP1R and prediabetes syndrome: However, the very small clinical experience on the use of DPP-4 inhibitors and GLP-1 mimetics in individuals with impaired fasting glucose or impaired glucose tolerance and the unsolved aspects related to the possibility of pancreatic side-effects do not recommend incretin-based therapies as an option for treatment in patients with prediabetes.